Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. - Wikidata - awgldk - TriplyDB

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33437383

about

miR-106b-5p promotes renal cell carcinoma aggressiveness and stem-cell-like phenotype by activating Wnt/β-catenin signalling.Targeting MicroRNAs in Cancer Gene Therapy.Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities.A New Network-Based Strategy for Predicting the Potential miRNA-mRNA Interactions in Tumorigenesis.EMT: Present and future in clinical oncology.The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas.The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling.miRNAs: micro-managers of anticancer combination therapies.MicroRNAs in gynecological cancers: Small molecules with big implications.The role of microRNAs in colorectal liver metastasis: Important participants and potential clinical significances.MicroRNA-Directed Neuronal Reprogramming as a Therapeutic Strategy for Neurological Diseases.Targeting MicroRNAs in Prostate Cancer Radiotherapy.Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression.The Clinical Application of MicroRNAs in Infectious Disease MicroRNA-34a: A Versatile Regulator of Myriads of Targets in Different Cancers.Small RNAs May Answer Big Questions in Mental Illness.Alternative mechanisms of miR-34a regulation in cancer.The role of miRNA and lncRNA in gastric cancer.Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.N-AC-l-Leu-PEI-mediated miR-34a delivery improves osteogenic differentiation under orthodontic force.miR-34a expression in human breast cancer is associated with drug resistance.Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines.microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.RNA interference-based therapy and its delivery systems.Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: Diagnosis and therapeutic implications.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs: miR-19b-1 role.Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project.Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment.Hiding in Plain Sight: Rediscovering the Importance of Noncoding RNA in Human Malignancy.Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143.Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy.Expression of miR-34a in T-Cells Infected by Human T-Lymphotropic Virus 1.Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript.Modulation of intracellular calcium signaling by microRNA-34a-5p A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases

P2860

Q33591563-83F07DB6-48F7-45D4-8CDA-D11311469BE4 Q37628264-C349D3EC-C1EF-478E-B125-398C37BE45DE Q37737945-26BB8533-60B9-40EB-B2F8-60B18B848B8F Q38613166-BD451507-BC82-4580-B3D6-783A0E2F82FD Q38673790-F960C9D2-1529-42E7-ACFA-D8EF98E87399 Q38683271-8ED4BB93-9674-4FD5-8BB9-46B723A8D36D Q39175956-9D5E76B5-C29D-432E-A7ED-4AB3A0FB8B63 Q39285150-9F59A280-B71F-498E-9132-FB6F73BAB398 Q39333266-6C741B4C-2A3B-46A7-ACC3-7AC82EB3B829 Q39398929-A8C7B501-ADA5-4C64-A17E-C492D8B26496 Q39406392-6E10B027-7F8F-412B-A0AB-A687C3F24647 Q41239908-01066418-8A1F-46E5-AB2D-FFDA0A5241FF Q41552623-82D0A3BA-ACCA-4C1F-A68C-DB030C5C47A4 Q41921194-1CBC5572-C51A-417E-BEDA-F821956F8B34 Q44463289-CD927AC0-38FA-4C46-AF1C-8C6719309025 Q47112089-81406E2D-E351-44DE-B223-BA7546CA8774 Q47117322-46CE04BB-0EEB-466A-AB98-0DAA0969D1FA Q47117573-542BC41D-BAFD-4698-ADFA-9756D599E11D Q47133472-2669B59F-DD2C-44BC-86FC-345BA8052868 Q47135875-4F2FFF82-AE21-4508-ADA1-F6B6E5B5D524 Q47139724-87C257DF-6314-4BE3-A3CD-65D77EAFF65E Q47145765-81B6BFE1-36A3-456B-B3F4-E3B1990D5FD0 Q47224057-9DF6AA38-AD6F-4588-9419-E3474CDD330C Q47375547-175B8DA7-0517-428D-9FE4-E642717F5DA3 Q47565462-9CF11B00-C98D-4053-B65E-57B4E3AA6F35 Q47767814-FD67304D-1227-4EAD-AA38-2FCA559041C4 Q48263612-5B2D3910-6BA4-4F15-A427-6A1D481C1FA5 Q48297890-DBFDC007-18BD-46E6-B52B-1E7F90CDF404 Q48308048-29A27427-A426-45F0-B13C-96FEE7568A21 Q50092033-2F879065-FB31-4A90-A090-64B1F0CB6B40 Q52562510-361C175A-710A-444E-896D-6D02BBD8317C Q52579251-2D417732-7E19-452F-82AD-D7FA5DB81A9B Q52597886-F26325F5-9B80-4F5D-B6A9-BF78D1ACFFEA Q52618071-73F22AD3-5D26-4FD5-B345-EC8BF43EFB15 Q52677215-90B47D0C-855E-4308-BCD8-2622F8A3C016 Q52726764-313218F1-CA7F-4411-A2A2-D6225BFAF4E6 Q54205015-09146128-CCE6-47ED-BCC6-9E61D44B8002 Q55266977-E8831A81-834C-40A4-AA3D-60A0E04F81AF Q57148008-7988FD05-E2A8-46E3-9FBB-CB0A9A34B562 Q57169221-A2A7B6FC-8682-4D21-866D-95F71F6BA509

P2860

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33437383

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Phase I study of MRX34, a lipo ...... ts with advanced solid tumors.

@ast

Phase I study of MRX34, a lipo ...... ts with advanced solid tumors.

@en

type

label

Phase I study of MRX34, a lipo ...... ts with advanced solid tumors.

@ast

Phase I study of MRX34, a lipo ...... ts with advanced solid tumors.

@en

prefLabel

Phase I study of MRX34, a lipo ...... ts with advanced solid tumors.

@ast

Phase I study of MRX34, a lipo ...... ts with advanced solid tumors.

@en

P1433

Q33437383-38C6EAB4-8099-4162-9A48-639BF4D7CA43

P1476

Q33437383-1E71BD67-CCA2-4804-A7D6-F78E2479A7F0

P2093

Q33437383-221E0F74-F021-44B5-B8CE-3FF468BF5B33

Q33437383-2A1EE057-30FF-4D40-BA42-B82CD7753F4A

Q33437383-30420B25-2C82-4716-8B38-CBB6974DA3ED

Q33437383-3E4C53C1-99C4-4B3B-A79A-692572888387

Q33437383-422DB655-D702-4B5D-9391-F9627F216C9C

Q33437383-4CC331CD-0125-4608-815D-AE37D9FBDA50

Q33437383-4D819745-5917-4D61-9227-AD5614A40946

Q33437383-7EDFBE4F-68CF-4802-9DA1-E4A02BFDCBBF

Q33437383-8B240C32-3E03-442F-974F-ECC7FFCCD6B7

Q33437383-E44BAAD9-04E0-490D-A413-C46CAF568340

P2860

Q33437383-03940158-2A16-44A3-989A-C0F5EEE4C5D4

Q33437383-04FFB3D7-DE04-4320-9949-AD170B6E61D2

Q33437383-074B84B8-302D-474C-B194-FD04CE6C1414

Q33437383-0956C9E6-3730-4FBE-B660-F1C6278B4851

Q33437383-09C7CF50-AAAF-4C7C-A445-8C83CFF675CB

Q33437383-0B693935-DF1A-4513-A3F4-737E8D460A07

Q33437383-11294BC5-5FF8-4A43-A4B7-BCA693942149

Q33437383-17B9F17D-7ADA-4D2F-A864-CC54D140CA77

Q33437383-17DFA87A-017F-4C31-97EE-945D90F23AD8

Q33437383-1AAD3E5A-F1BD-4C1F-B501-A1DE8A6C1685

P2888

Q33437383-4552AFD0-98F4-4DE8-922F-C9D52DD5D910

P304

Q33437383-71F5E486-D3FC-49FC-90EC-49E9090667F4

P31

Q33437383-AF782572-94E7-4BBE-8D0C-323660EBA615

P356

Q33437383-452087CA-58BF-43C0-A6C6-1EF8252D051C

P433

Q33437383-7A3A3C7D-33E0-4EAB-A4D5-3720DECAEDE7

P478

Q33437383-661A3943-1E86-455E-A796-D0B4211C0C84

P577

Q33437383-2B8B1F1D-DC90-46EC-87D2-7F856F10E446

P6179

Q33437383-7EAA1868-DB3A-40F3-97DF-69B028D27A24

P698

Q33437383-BA393A18-75BB-4317-84D4-7CD21D856AF7

P932

Q33437383-2E5064C3-BFFB-44B7-9B00-BA776F12B525

P356

S10637-016-0407-Y

P1433

Investigational New Drugs

P1476

Phase I study of MRX34, a lipo ...... ts with advanced solid tumors.

@en

P2093

Andreas G Bader

http://www.w3.org/2001/XMLSchema#string

Andrew J Brenner

http://www.w3.org/2001/XMLSchema#string

David S Hong

http://www.w3.org/2001/XMLSchema#string

Jasgit Sachdev

http://www.w3.org/2001/XMLSchema#string

Jay Stoudemire

http://www.w3.org/2001/XMLSchema#string

Mitesh Borad

http://www.w3.org/2001/XMLSchema#string

Muhammad S Beg

http://www.w3.org/2001/XMLSchema#string

Sinil Kim

http://www.w3.org/2001/XMLSchema#string

Susan Smith

http://www.w3.org/2001/XMLSchema#string

Yoon-Koo Kang

http://www.w3.org/2001/XMLSchema#string

P2860

MicroRNAs: target recognition and regulatory functions

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

Immune Checkpoint Blockade in Cancer Therapy

dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects

Oncomirs - microRNAs with a role in cancer

MicroRNA signatures in human cancers

MicroRNAs: genomics, biogenesis, mechanism, and function

The miR-34 family in cancer and apoptosis

In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation

Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34

P2888

s10637-016-0407-y

P304

180-188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-016-0407-Y

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1030443771

http://www.w3.org/2001/XMLSchema#string

P698

27917453

http://www.w3.org/2001/XMLSchema#string

P932

5893501

http://www.w3.org/2001/XMLSchema#string